Angioimmunoblastic T-cell lymphoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:86886C86.5
Who is this for?
Show terms as
8Active trials51Specialists8Treatment centers

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

AILTImmunoblastic lymphadenopathyLymphogranulomatosis XT-cell lymphoma, AILD type
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

City of Hope Medical Center — PHASE1

TrialNOT YET RECRUITING
Aug 2025Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

The Affiliated Hospital of Xuzhou Medical University — PHASE2

TrialRECRUITING
May 2025A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

SecuraBio — PHASE3

TrialRECRUITING
Apr 2025Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

The Affiliated Hospital of Xuzhou Medical University — PHASE2

TrialRECRUITING
Dec 2024A Study of Enasidenib in People With T-Cell Lymphoma

Memorial Sloan Kettering Cancer Center — PHASE2

TrialRECRUITING
Sep 2024A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Arvinas Inc. — PHASE1

TrialRECRUITING
Dec 2023A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Regeneron Pharmaceuticals — PHASE3

TrialRECRUITING
Oct 2023Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

Zhengzhou University — PHASE4

TrialACTIVE NOT RECRUITING
Aug 2022A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Janssen Research & Development, LLC — PHASE1

TrialACTIVE NOT RECRUITING
Nov 2019A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

Regeneron Pharmaceuticals — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Angioimmunoblastic T-cell lymphoma.

8 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

8 recruitingView all trials with filters →
Phase 33 trials
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Phase 3
Active
PI: Bristol-Myers Squibb (Bristol-Myers Squibb) · Sites: Sapporo, Hokkaido; Okayama, Okayama-ken +10 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL
Phase 3
Active
PI: Jehan DUPUIS, MD (Henri Mondor University Hospital) · Sites: Graz; Vienna +25 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Phase 3
Actively Recruiting
· Sites: Ghent; Leuven +41 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 41 trial
Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight
Phase 4
Active
· Sites: Zhengzhou, Henan · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 23 trials
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
Phase 2
Actively Recruiting
PI: Wei Sang Doctor · Sites: Xuzhou, Jiangsu · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Study of Enasidenib in People With T-Cell Lymphoma
Phase 2
Actively Recruiting
PI: Zachary Epstein-Peterson, MD (Memorial Sloan Kettering Cancer Center) · Sites: Boston, Massachusetts; Basking Ridge, New Jersey +6 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Phase 2
Actively Recruiting
· Sites: Xuzhou, Jiangsu · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 11 trial
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1
Actively Recruiting
· Sites: New Haven, Connecticut; Detroit, Michigan +15 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 51View all specialists →
CO
Choon Kiat Ong
Specialist
2 Angioimmunoblastic T-cell lymphoma publications
SH
Steven M Horwitz
Specialist
2 Angioimmunoblastic T-cell lymphoma publications
EJ
Elaine S Jaffe
BETHESDA, MD
Specialist
1 Angioimmunoblastic T-cell lymphoma publication
MS
Mostafa F Mohammed Saleh
SANTA BARBARA, CA
Specialist
1 Angioimmunoblastic T-cell lymphoma publication
LL
Laurence de Leval
Specialist
2 Angioimmunoblastic T-cell lymphoma publications
CW
Chong Wei
FLUSHING, NY
Specialist
2 Angioimmunoblastic T-cell lymphoma publications
GI
Giorgio Inghirami
NEW YORK, NY
Specialist
3 Angioimmunoblastic T-cell lymphoma publications
XZ
Xudong Zhang
Specialist
2 Angioimmunoblastic T-cell lymphoma publications
MZ
Mingzhi Zhang
Specialist
2 Angioimmunoblastic T-cell lymphoma publications
WL
Weiping Liu
Specialist
2 Angioimmunoblastic T-cell lymphoma publications
MX
Mina L Xu
NEW HAVEN, CT
Specialist
1 Angioimmunoblastic T-cell lymphoma publication
NM
Nana P Matsumoto
PITTSBURGH, PA
Specialist
1 Angioimmunoblastic T-cell lymphoma publication
SL
Soon Thye Lim
HICKSVILLE, NY
Specialist
2 Angioimmunoblastic T-cell lymphoma publications
YX
Yi Xie
Specialist
1 Angioimmunoblastic T-cell lymphoma publication
DM
David Maloney
Specialist
PI on 11 active trials
JV
Julie M Vose
MANCHESTER, NH
Specialist
PI on 2 active trials
EM
Eric Jacobsen, MD
Specialist
PI on 4 active trials
PM
Paolo Caimi, MD
CLEVELAND, OH
Specialist
PI on 5 active trials
TM
Thomas G. Martin, MD
Specialist
PI on 4 active trials
BM
Bradford S. Hoppe, MD, MPH
JACKSONVILLE, FL
Specialist
PI on 2 active trials
JM
Jonathan Moreira, MD
CHICAGO, IL
Specialist
PI on 2 active trials
TM
Thomas E. Witzig, MD
ROCHESTER, MN
Specialist
PI on 9 active trials
ML
Matthew A Lunning
OMAHA, NE
Specialist
PI on 1 active trial
NR
Nancy Wells, DNSc, RN
Specialist
PI on 2 active trials
FZ
Francesco Zaja
Specialist
PI on 2 active trials2 Angioimmunoblastic T-cell lymphoma publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Angioimmunoblastic T-cell lymphoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Angioimmunoblastic T-cell lymphomaForum →

No community posts yet. Be the first to share your experience with Angioimmunoblastic T-cell lymphoma.

Start the conversation →

Latest news about Angioimmunoblastic T-cell lymphoma

1 articles
Clinical trialUNITERAREApr 3, 2026
New Recruiting Trial: Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Researchers are testing a new type of cell therapy made from umbilical cord blood to treat T-cell lymphoma that has stopped responding to other treatments. The …
See all news about Angioimmunoblastic T-cell lymphoma →

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Angioimmunoblastic T-cell lymphoma

Are there clinical trials for Angioimmunoblastic T-cell lymphoma?

Yes — 8 recruiting clinical trials are currently listed for Angioimmunoblastic T-cell lymphoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Angioimmunoblastic T-cell lymphoma?

25 specialists and care centers treating Angioimmunoblastic T-cell lymphoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.